IL163655A0 - Anti-ccr5 antibody - Google Patents

Anti-ccr5 antibody

Info

Publication number
IL163655A0
IL163655A0 IL16365503A IL16365503A IL163655A0 IL 163655 A0 IL163655 A0 IL 163655A0 IL 16365503 A IL16365503 A IL 16365503A IL 16365503 A IL16365503 A IL 16365503A IL 163655 A0 IL163655 A0 IL 163655A0
Authority
IL
Israel
Prior art keywords
atcc deposit
deposit designation
plasmid designated
designation pta
ccr5
Prior art date
Application number
IL16365503A
Other languages
English (en)
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of IL163655A0 publication Critical patent/IL163655A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL16365503A 2002-02-22 2003-02-21 Anti-ccr5 antibody IL163655A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8112802A 2002-02-22 2002-02-22
PCT/US2003/005500 WO2003072766A1 (fr) 2002-02-22 2003-02-21 Anticorps anti-ccr5

Publications (1)

Publication Number Publication Date
IL163655A0 true IL163655A0 (en) 2005-12-18

Family

ID=27765254

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16365503A IL163655A0 (en) 2002-02-22 2003-02-21 Anti-ccr5 antibody

Country Status (19)

Country Link
EP (2) EP2058006A1 (fr)
JP (1) JP2006508631A (fr)
KR (1) KR20050004784A (fr)
CN (1) CN1780907B (fr)
AT (1) ATE414142T1 (fr)
AU (1) AU2003217674C1 (fr)
CA (1) CA2476901C (fr)
CY (1) CY1108799T1 (fr)
DE (1) DE60324664D1 (fr)
DK (1) DK1478738T3 (fr)
ES (1) ES2316740T3 (fr)
IL (1) IL163655A0 (fr)
MX (1) MXPA04008153A (fr)
NO (1) NO20043971L (fr)
NZ (2) NZ561465A (fr)
PT (1) PT1478738E (fr)
RU (1) RU2322454C2 (fr)
WO (1) WO2003072766A1 (fr)
ZA (1) ZA200406765B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CA2664752A1 (fr) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Anticorps diriges contre le ccr5 et ses utilisations
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
CA2736029A1 (fr) * 2008-09-05 2010-03-11 Duke University Anticorps antilipidiques
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
WO2013024022A1 (fr) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
US11584797B2 (en) 2015-06-23 2023-02-21 Cytodyn Inc. Inhibition of CCL5 ligand binding to CCR5 receptor and alteration of CCR5/CCL5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2017087547A1 (fr) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Agents de liaison à pd-l1 et leurs utilisations
EP4090675A4 (fr) * 2020-01-13 2024-02-21 CytoDyn Inc. Agent de liaison à ccr5 pour le traitement du cancer du sein métastatique ccr5-positif
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH03505579A (ja) * 1988-06-30 1991-12-05 デービス，マイクル，エイチ ヒト免疫不全ウイルス（ｈｉｖ）のインビボにおける活性の阻害方法
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
DK1144006T3 (da) * 1998-12-16 2007-11-26 Progenics Pharm Inc Synergistisk inhibering af HIV-1-fusion og -binding, præparater og antistoffer dertil
JP3459386B2 (ja) 1999-10-15 2003-10-20 Ｓｍｃ株式会社 可逆式取付機構を有する流体圧機器
US20030049251A1 (en) * 1999-12-08 2003-03-13 Barbas Carlos F. Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease

Also Published As

Publication number Publication date
PT1478738E (pt) 2009-02-16
MXPA04008153A (es) 2005-07-05
DK1478738T3 (da) 2009-03-09
EP2058006A1 (fr) 2009-05-13
EP1478738A4 (fr) 2006-05-31
NZ534947A (en) 2008-03-28
EP1478738B1 (fr) 2008-11-12
RU2322454C2 (ru) 2008-04-20
EP1478738A1 (fr) 2004-11-24
AU2003217674A1 (en) 2003-09-09
AU2003217674C1 (en) 2009-03-26
DE60324664D1 (de) 2008-12-24
WO2003072766A1 (fr) 2003-09-04
NO20043971L (no) 2004-11-16
CN1780907B (zh) 2011-06-15
CA2476901C (fr) 2012-10-09
ATE414142T1 (de) 2008-11-15
CY1108799T1 (el) 2014-04-09
RU2004128252A (ru) 2005-04-10
NZ561465A (en) 2009-04-30
CN1780907A (zh) 2006-05-31
JP2006508631A (ja) 2006-03-16
KR20050004784A (ko) 2005-01-12
ES2316740T3 (es) 2009-04-16
HK1072272A1 (en) 2005-08-19
ZA200406765B (en) 2006-06-28
AU2003217674B2 (en) 2008-10-30
CA2476901A1 (fr) 2003-09-04

Similar Documents

Publication Publication Date Title
CY1108799T1 (el) Αντισωμα αντι- ccr5
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
WO2003055527A3 (fr) Nouveaux immunoconjugues utiles pour le traitement de tumeurs
NZ590690A (en) Antibodies that bind to p-selectin glycoprotein ligand 1
IN2009KN02655A (fr)
SG55079A1 (en) Multivalent single chain antibodies
PT778891E (pt) Anticorpo monoclonal recombinante anti-rhesus d (d7c2)
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
FI4209510T3 (fi) Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
GEP20105118B (en) Anti-vegf antibodies
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
NZ598594A (en) Combinatorial therapy involving alpha5beta1 antagonists
NZ612796A (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
GB9300686D0 (en) Compounds for targeting
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
EP2267034A3 (fr) Protéine de liaison or et utilisation en conséquence
AU2003273423A1 (en) Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
NZ527173A (en) Specific human antibodies for selective cancer therapy
EP1712565A4 (fr) Agents induisant la mort cellulaire